Anti-APLP1 monoclonal antibody and use thereof

The anti-APLP1 monoclonal antibody enables the collection and detection of neuropsychiatric disorder biomarkers in peripheral blood, addressing the limitations of invasive and costly traditional methods by specifically targeting extracellular vesicles from brain nerve cells, facilitating non-invasive and cost-effective dementia diagnosis.

WO2024237108A1PCT designated stage expired Publication Date: 2024-11-21OSAKA UNIVERSITY +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/016798
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-01
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current dementia diagnosis methods using biomarkers are invasive and costly, with a need for less invasive and cost-effective alternatives, particularly in peripheral blood, to detect neuropsychiatric disorders effectively.

Method used

Development of an anti-APLP1 monoclonal antibody that specifically binds to extracellular vesicles derived from brain nerve cells, allowing for the collection and detection of biomarkers such as tau protein in peripheral blood, using a method involving the formation of a complex with these antibodies and subsequent recovery of extracellular vesicles.

Benefits of technology

Enables the detection of neuropsychiatric disease biomarkers with high specificity and sensitivity in peripheral blood, reducing the invasiveness and cost associated with traditional methods, and providing a non-invasive means to assess conditions like Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JPOXMLDOC01-APPB-T000001
    Figure JPOXMLDOC01-APPB-T000001
  • Figure JPOXMLDOC01-APPB-T000002
    Figure JPOXMLDOC01-APPB-T000002
  • Figure JPOXMLDOC01-APPB-T000003
    Figure JPOXMLDOC01-APPB-T000003
Patent Text Reader

Abstract

The present invention pertains to: an anti-APLP1 monoclonal antibody of which the epitope is the amino acid sequence from no. 232 to no. 238 in SEQ ID NO. 1; and an anti-APLP1 monoclonal antibody in which CDR1, CDR2, and CDR3 in a light chain respectively have the amino acid sequences described in SEQ ID NO. 5, 7, and 9, and CDR1, CDR2, and CDR3 in a heavy chain respectively have the amino acid sequences described in SEQ ID NO. 12, 14, and 16. The present invention also pertains to: a method for recovering extracellular vesicles derived from brain neurons by using the anti-APLP1 monoclonal antibody of the present invention; methods for detecting a neuropsychiatric disease biomarker and for recovering neuron-derived components, the methods each comprising recovering extracellular vesicles by said method; and a test reagent and a test kit which are for use in recovering extracellular vesicles and which include the anti-APLP1 monoclonal antibody of the present invention. The present invention provides: an anti-APLP1 monoclonal antibody having a higher specificity with respect to NDE; a method for recovering extracellular vesicles by using said antibody; a method for detecting a neuropsychiatric disease biomarker using the recovered extracellular vesicles; a test drug; and a test kit.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-APLP1 monoclonal antibody and its use

[0001] The present invention relates to an anti-APLP1 monoclonal antibody and uses thereof. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to Japanese Patent Application No. 2023-79084, filed May 12, 2023, the entire disclosure of which is specifically incorporated herein by reference.

[0002] Countermeasures against dementia are a major issue today, and methods for diagnosing dementia using biomarkers are being developed. However, these methods rely on imaging diagnostics such as PET scans or cerebrospinal fluid diagnostics, which have been criticized for their cost and invasiveness. Therefore, there is a need to develop biomarkers that use peripheral blood samples, which are less invasive and less expensive.

[0003] Extracellular vesicles (exosomes) are released from various cells into body fluids such as blood. Therefore, neuron-derived extracellular vesicles (NDEs) are present in the blood. NDEs are surrounded by a lipid bilayer, protecting their contents from proteolytic and nucleolytic enzymes and preserving the environment of brain cells. Furthermore, because the membrane of NDEs reflects that of brain neurons, neuron-specific proteins are present on the NDE membrane. One of these is amyloid beta precursor-like protein 1 (APLP1). A schematic diagram of an NDE presenting APLP1 on the NDE membrane is shown in Figure 1.

[0004] Patent Document 1: WO2021 / 132352

[0005] Non-Patent Document 1: Alzheimer's & Dementia 15 (2019) 1071-1080 The entire disclosures of Patent Document 1 and Non-Patent Document 1 are each specifically incorporated herein by reference.

[0006] Patent Document 1 discloses a method for recovering extracellular vesicles using an anti-APLP1 antibody, a method for detecting neuropsychiatric disorders using the recovered extracellular vesicles, a test agent, a test kit, etc. The anti-APLP1 antibody used in the invention described in Patent Document 1 is a commercially available antibody and is a polyclonal antibody.

[0007] Non-Patent Document 1 describes a method for recovering NDE using an anti-NCAM antibody (mouse anti-human neural cell adhesion molecule (NCAM)). The anti-NCAM antibody is an antibody that shows reactivity with a completely different target than the anti-APLP1 antibody.

[0008] The present invention aims to provide an anti-APLP1 monoclonal antibody, which is a new antibody with higher specificity for NDE, and to provide a method for recovering extracellular vesicles using this anti-APLP1 monoclonal antibody, a method for detecting biomarkers for neuropsychiatric disorders using the recovered extracellular vesicles, a test agent, a test kit, etc.

[0009] The present inventors focused on the integral membrane protein of NDE and prepared several monoclonal antibodies that recognize specific sites of this protein as epitopes. From among these, they discovered an anti-APLP1 monoclonal antibody that specifically binds to NDE, and completed inventions relating to a method for recovering NDE using this anti-APLP1 monoclonal antibody, a method for detecting biomarkers for neuropsychiatric disorders using the recovered NDE, a test agent, and a test kit.

[0010] The present invention is as follows: [1] An anti-APLP1 monoclonal antibody having as its epitope the amino acid sequence from positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing. [2] An anti-APLP1 monoclonal antibody in which CDR1, CDR2, and CDR3 of the light chain have the amino acid sequences set forth in SEQ ID NOs: 5, 7, and 9, respectively, and CDR1, CDR2, and CDR3 of the heavy chain have the amino acid sequences set forth in SEQ ID NOs: 12, 14, and 16, respectively. [3] The anti-APLP1 monoclonal antibody according to [2], in which FR1, FR2, FR3, and FR4 of the light chain have the amino acid sequences set forth in SEQ ID NOs: 4, 6, 8, and 10, respectively, and FR1, FR2, FR3, and FR4 of the heavy chain have the amino acid sequences set forth in SEQ ID NOs: 11, 13, 15, and 17, respectively. [4] A method for recovering extracellular vesicles derived from brain neurons, comprising: mixing an anti-APLP1 antibody with a sample containing extracellular vesicles to form a complex of the anti-APLP1 antibody and the extracellular vesicles; and recovering the complex of the anti-APLP1 antibody and the extracellular vesicles, wherein the anti-APLP1 antibody is the anti-APLP1 monoclonal antibody described in any one of [1] to [3]. [5] The recovery method described in [4], wherein the sample containing extracellular vesicles is plasma. [6] A method for detecting a biomarker for neuropsychiatric disorders, comprising: recovering extracellular vesicles by the method described in [4] or [5], and obtaining measurements of polypeptides and / or polynucleotides that serve as biomarkers for neuropsychiatric disorders from the recovered extracellular vesicles. [7] The detection method described in [6], further comprising: comparing the obtained measurements with corresponding reference values ​​and determining whether the measurements are within or outside the reference range. [8] The detection method described in [6] or [7], wherein the biomarker is tau protein or phosphorylated tau protein. [9] A method for recovering components derived from brain neurons, comprising the steps of recovering extracellular vesicles by the method described in [4] or [5], and recovering at least one biomolecule selected from the group consisting of sugars, lipids, polypeptides, and polynucleotides from the recovered extracellular vesicles.

[10] A test reagent used for recovering extracellular vesicles, comprising the anti-APLP1 monoclonal antibody described in any of [1] to [3].

[11] The test reagent according to

[10] , which is used to carry out the method for recovering extracellular vesicles according to [4] or [5].

[12] The test reagent according to

[10] , which is used to carry out the method for detecting a biomarker for neuropsychiatric disorders according to any one of [6] to [8].

[13] The test reagent according to

[10] , which is used to carry out the method for recovering components derived from brain neurons according to [9].

[14] A test kit comprising the test reagent according to

[10] .

[0011] According to the present invention, an anti-APLP1 monoclonal antibody that specifically binds to an NDE can be provided. Furthermore, according to the present invention, a method for recovering an NDE and a method for detecting a biomarker for a neuropsychiatric disorder using the recovered NDE can be provided.

[0012] FIG. 1 shows a schematic diagram of an NDE displaying APLP1 on an NDE membrane. FIG. 2 shows the amino acid sequence of human APLP1 (NCBI accession No. NP_031493.2) (SEQ ID NO: 1). FIG. 3 shows the results of analysis using a flow cytometer in Example 1-1. FIG. 4 shows the results of ELISA analysis of the reactivity of the antibody obtained in Example 1-1 with the APLP1 peptide. FIG. 5 shows the results of immunostaining in Example 1-1. FIG. 6 shows the results of Western blotting in Example 1-1. FIG. 7 shows the results of cell staining in Example 1-2. FIG. 8 shows the results of WB analysis of an extract from 293FT cells in which APLP1 was forcibly expressed in Example 1-3(1). FIG. 9 shows the results of signal detection by cell staining in Example 1-3(2). FIG. 10-1 shows the results of Western blotting in Example 2. Figure 10-2 shows the comparative results of Western blotting using the specific monoclonal antibody #11 of the present invention and a commercially available polyclonal antibody in Example 2. Figure 11 shows the results of Western blotting in Example 3. Figure 12 shows a scatter plot showing the correlation between the amount of total tau in plasma brain neuron-derived extracellular vesicles (NDE) and the total tau in cerebrospinal fluid (CSF) in Example 4. Figure 13 shows a scatter plot showing the correlation between the amount of total tau in plasma brain neuron-derived extracellular vesicles (NDE) and phosphorylated tau (pTau181) in cerebrospinal fluid (CSF) (left panel) and the Aβ42 / Aβ40 ratio in cerebrospinal fluid (CSF) (right panel) in Example 4.

[0013] 1. Anti-APLP1 Monoclonal Antibody A first embodiment of the anti-APLP1 monoclonal antibody of the present invention is an anti-APLP1 monoclonal antibody having as its epitope the amino acid sequence of positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing. An anti-APLP1 monoclonal antibody having as its epitope the amino acid sequence of positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1 is an antibody that recognizes as an antigen a peptide having the amino acid sequence of positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1. Recognition of a peptide having the amino acid sequence of positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1 as an antigen can be determined by the antibody showing reactivity with a peptide having the amino acid sequence of positions 232 to 238. The reactivity of an antibody with a peptide can be tested by conventional methods, such as flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), Western blot, fluorescence microanalysis (FMAT), surface plasmon resonance (BIAcore), immunostaining, immunoprecipitation, and the like.

[0014] APLP1 (amyloid beta precursor-like protein 1) is an integral membrane protein of extracellular vesicles (NDEs) derived from brain neurons and a member of the amyloid precursor protein gene family. APLP1 protein is expressed in the brain and is a membrane-bound glycoprotein that is cleaved by secretases, similar to the cleavage of the amyloid beta A4 precursor protein. This cleavage releases an intracellular cytoplasmic fragment that may act as a transcriptional activator.

[0015] Brain cells may include, for example, neurons and glial cells. Glial cells may include astrocytes, oligodendrocytes, and microglial cells. Extracellular vesicles are particles with a size of approximately tens to thousands of nanometers that are released from cells and are covered with a membrane composed primarily of phospholipids.

[0016] Human APLP1 is registered, for example, under Gene ID: 333. The NCBI Reference Sequence is, for example, NM_001024807.3. In the present invention, the human APLP1 peptide has the amino acid sequence set forth in SEQ ID NO: 1 in the sequence listing.

[0017] A first embodiment of the anti-APLP1 monoclonal antibody of the present invention is an anti-APLP1 monoclonal antibody whose epitope is the amino acid sequence from positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing. As shown in the Examples, the amino acid sequence from positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO: 1 in the Sequence Listing is the minimum amino acid sequence required for the epitope.

[0018] A second embodiment of the anti-APLP1 monoclonal antibody of the present invention is an anti-APLP1 monoclonal antibody in which the CDR1, CDR2, and CDR3 of the light chain have the amino acid sequences of SEQ ID NOs: 5, 7, and 9, respectively, and the CDR1, CDR2, and CDR3 of the heavy chain have the amino acid sequences of SEQ ID NOs: 12, 14, and 16, respectively. In the second embodiment of the anti-APLP1 monoclonal antibody of the present invention, preferably the FR1, FR2, FR3, and FR4 of the light chain have the amino acid sequences of SEQ ID NOs: 4, 6, 8, and 10, respectively, and the FR1, FR2, FR3, and FR4 of the heavy chain have the amino acid sequences of SEQ ID NOs: 11, 13, 15, and 17, respectively.

[0019] The amino acid sequences of the light and heavy chains, represented by their respective SEQ ID NOs, are shown in Tables 1 and 2 below.

[0020]

[0021]

[0022] The anti-APLP1 monoclonal antibody of the present invention is not particularly limited in terms of immunoglobulin class and subclass, and may be, for example, IgG. Furthermore, the anti-APLP1 monoclonal antibody may be obtained in the form of a fragment (e.g., Fab, F(ab'), F(ab)). 2 etc.), chimeric antibodies, scFvs, etc.

[0023] Method for Producing Anti-APLP1 Monoclonal Antibody of the Present Invention The anti-APLP1 monoclonal antibody of the present invention can be produced using the methods described in, for example, Kurosawa et al., "Rapid production of antigen-specific monoclonal antibodies from a variety of animals" BMC Biology 2021, 10:80 (Non-Patent Document 2), Kurosawa et al., "Novel method for the high-throughput production site-specific monoclonal antibodies" SCIENTIFIC REPORT 6:25174 DOI:10.1038 srep25174 (Non-Patent Document 3), and WO2011 / 027808 (Patent Document 2) and WO2012 / 133572 (Patent Document 3). The entire disclosures of Patent Documents 2 and 3, and Non-Patent Documents 2 and 3, respectively, are expressly incorporated herein by reference.

[0024] Monoclonal antibodies whose light and heavy chain amino acid sequences are specified, and anti-APLP1 monoclonal antibodies whose light chain CD1, CD2, and CD3, FR1, FR2, FR3, and FR4 amino acid sequences and heavy chain CD1, CD2, and CD3, FR1, FR2, FR3, and FR4 amino acid sequences can be produced by known methods, including, but not limited to, the methods described in Non-Patent Documents 2 and 3 and Patent Documents 2 and 3.

[0025] Monoclonal antibodies with an epitope on an integral membrane protein of extracellular vesicles derived from brain neurons can be produced by immunizing an animal with the desired amino acid fragment (target antigen), collecting lymph or lymphoid tissue from the immunized animal, harvesting cells from the lymph or lymphoid tissue, and recovering specific plasma cells reactive with the target antigen from the collected cells. cDNA is synthesized from the recovered target antigen-specific plasma cells, and the γ-chain and κ-chain variable region genes are amplified using this as a template. The amplified variable regions are then inserted into an expression vector to obtain the variable region genes. The resulting γ-chain and κ-chain variable region genes are used to generate heavy and light chain immunoglobulin genes, which are then transfected into, for example, 293FT cells to produce recombinant antibodies. If necessary, antibodies with high reactivity to the target antigen can be selected from the multiple recombinant antibodies produced. Specific methods are described in Example 1.

[0026] 2. Method for recovering extracellular vesicles This embodiment relates to a method for recovering extracellular vesicles derived from brain neurons. The method for recovering extracellular vesicles includes the steps of mixing an anti-APLP1 monoclonal antibody (hereinafter sometimes referred to as anti-APLP1 antibody) with a sample containing extracellular vesicles, and recovering a complex of the anti-APLP1 antibody and the extracellular vesicles. By mixing the anti-APLP1 antibody with a sample containing extracellular vesicles, a complex can be formed between the anti-APLP1 antibody and the extracellular vesicles.

[0027] Extracellular vesicles include exosomes, microvesicles, apoptotic bodies, and the like. In many cases, biomolecules are present in extracellular vesicles. For example, exosomes or microvesicles contain at least one biomolecule selected from the group consisting of polypeptides and polypeptides (RNAs such as mRNA, miRNA, and non-coding RNA, and DNA). For example, apoptotic bodies contain at least one species selected from the group consisting of fragmented nuclei and organelles. Extracellular vesicles preferably contain at least one biomolecule selected from the group consisting of polypeptides and polypeptides. More preferably, extracellular vesicles contain at least one biomolecule selected from the group consisting of polypeptides and polypeptides. Here, polypeptide refers to a compound in which multiple amino acids are bound by peptide bonds, and includes proteins with relatively large molecular weights and peptides with relatively small molecular weights.

[0028] The sample contains extracellular vesicles roughly purified from a specimen containing extracellular vesicles. The sample may be a dispersion of extracellular vesicles or a pellet of extracellular vesicles.

[0029] Methods for crudely purifying extracellular vesicles from a sample are known, and extracellular vesicles can be crudely purified, for example, by size exclusion chromatography, ultracentrifugation, affinity purification, polymer precipitation, or a combination thereof. Known methods can be used as these crude purification methods. Size exclusion chromatography is not limited as long as it can fractionate extracellular vesicles by size. For example, size exclusion chromatography can be performed using the Extracellular Vesicle Extraction Kit qEV (Izon Science). Ultracentrifugation can be performed, for example, by ultracentrifugation at 100,000 g to 150,000 g for approximately 2 to 3 hours to obtain extracellular vesicles. Preferably, the sample is diluted with PBS, HEPES buffer, cell culture medium, or the like, as needed, so that the specific gravity is approximately 1.000 to 1.010 before ultracentrifugation. Affinity purification methods may include, for example, phosphatidylserine affinity purification, CD63 affinity purification, anion affinity purification, etc. Polymer precipitation is a method of precipitating extracellular vesicles using polyethers such as polyethylene glycol, polypropylene glycol, and polytetramethylene glycol. Crude purification of extracellular vesicles is preferably performed by a method capable of obtaining extracellular vesicles of approximately 70 nm to 1000 nm.

[0030] The specimen is collected from the living body of an animal, preferably a mammal such as a human, mouse, rat, rabbit, dog, cat, cow, pig, or horse, and is not limited as long as it contains extracellular vesicles. For example, the specimen includes whole blood, serum, plasma, lymph, urine, ascites, pleural effusion, cerebrospinal fluid, interstitial fluid, tears, nasal discharge, saliva, etc.

[0031] The anti-APLP1 antibody is the anti-APLP1 monoclonal antibody of the present invention. However, the antibody may be a complex bound to a carrier. Examples of the carrier include known carriers used in immunoprecipitation. For example, the carrier may be magnetic beads, agarose beads, cellulose beads, a microplate, a tube, etc.

[0032] The mixing of an anti-APLP1 antibody with a sample containing extracellular vesicles is not limited, as long as the conditions allow the anti-APLP1 antibody to bind to APLP1 present in the extracellular vesicles. Examples include Tris-HCl buffer, phosphate buffer, HEPES buffer, maleic acid buffer, CHAPS buffer, etc., with a pH of approximately 6 to 9. These buffers preferably contain sodium chloride at the same level as physiological saline. Furthermore, bovine serum albumin, skim milk, etc. may be added as a blocking reagent. The reaction temperature is approximately 4°C to 37°C. Furthermore, the reaction between the antibody and the extracellular vesicles is preferably carried out with stirring. The reaction time depends on the reaction temperature, but is approximately 4 to 48 hours when the reaction temperature is approximately 4°C, and approximately 0.5 to 4 hours when the reaction temperature is approximately 37°C.

[0033] Through the above reaction, the anti-APLP1 antibody binds to the extracellular vesicles, forming a complex of the anti-APLP1 antibody and the extracellular vesicles (also referred to as an "anti-APLP1 antibody-extracellular vesicle complex").

[0034] Anti-APLP1 antibody-extracellular vesicle complexes can be recovered by known methods. When the anti-APLP1 antibody is pre-bound to a carrier, a recovery method can be selected depending on the properties of the carrier. For example, when the carrier is magnetic beads, the anti-APLP1 antibody-extracellular vesicle complexes can be recovered by adsorbing them to a magnet. When the carrier is non-magnetic beads such as agarose beads or cellulose beads, the anti-APLP1 antibody-extracellular vesicle complexes can be recovered by centrifugation.

[0035] When the anti-APLP1 antibody is not pre-bound to a carrier, the anti-APLP1 antibody-extracellular vesicle complex can be recovered using a substance that has affinity for the antibody used, such as a secondary antibody that binds to the anti-APLP1 antibody, or a carrier bound to protein A or protein G. The method for recovering the carrier and the anti-APLP1 antibody-extracellular vesicle complex bound to the carrier is the same as when the anti-APLP1 antibody is pre-bound to a carrier.

[0036] The process for recovering the anti-APLP1 antibody-extracellular vesicle complex may include a washing step of the anti-APLP1 antibody-extracellular vesicle complex by performing B (bound) / F (free) separation to remove extracellular vesicles that have not reacted with the anti-APLP1 antibody, and anti-APLP1 antibody that has not reacted with the extracellular vesicles.

[0037] Because APLP1 is a protein that is specifically expressed in brain neurons, the above-described recovery method can recover extracellular vesicles derived from brain neurons. Because the anti-APLP1 monoclonal antibody of the present invention has high specific reactivity with human APLP1 peptides, it can specifically recover extracellular vesicles that have APLP1 peptides as membrane proteins.

[0038] One embodiment of the method for recovering extracellular vesicles includes a method for separating extracellular vesicles from plasma, comprising: (1) separating all extracellular vesicles from plasma by size exclusion chromatography; (2) immunoprecipitation of the total extracellular vesicle fraction using an anti-APLP1 monoclonal antibody; and (3) treating the obtained fraction with acid to separate the extracellular vesicles. Note that extracellular vesicles can also be separated by peptide treatment instead of acid treatment.

[0039] 3. Method for detecting biomarkers for neuropsychiatric disorders In this embodiment, biomarkers for neuropsychiatric disorders are detected using the extracellular vesicles collected in 2 above.

[0040] The method for detecting a biomarker for a neuropsychiatric disorder includes obtaining a measured value of a polypeptide and / or polynucleotide of a biomarker for a neuropsychiatric disorder from the extracellular vesicles collected in 2 above. The method for detecting a biomarker for a neuropsychiatric disorder may further include a step of comparing the measured value with a corresponding reference value and determining whether the measured value is within or outside the reference range. If the measured value is outside the reference range, it can be determined that the subject from whom the sample was collected is suffering from a neuropsychiatric disorder. Alternatively, if the measured value is within the reference range, it can be determined that the patient from whom the sample was collected is not suffering from a neuropsychiatric disorder.

[0041] Additionally, the severity of the neuropsychiatric disorder may be determined by determining the extent to which the measured values ​​deviate from the baseline values.

[0042] Neuropsychiatric disorders may include psychiatric disorders and neurological disorders. Nervous system disorders may include, for example, neurodegenerative disorders, neurological dysfunction after cerebrospinal trauma, brain tumors, cerebrospinal diseases associated with infections, and multiple sclerosis. Neurodegenerative disorders may include, for example, dementia, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, multiple system atrophy, and triplet repeat disease. Dementia may include, for example, Alzheimer's disease, senile dementia, Lewy body disease, frontotemporal dementia, vascular dementia, alcoholic dementia, and corticobasal degeneration. Infectious cerebrospinal diseases may include, for example, meningitis, brain abscess, Crotzfeldt-Jakob disease, and AIDS dementia. Brain tumors may include, for example, astrocytoma.

[0043] Psychiatric disorders can include, for example, schizophrenia, depression, and bipolar disorder.

[0044] For example, tau protein, particularly phosphorylated tau protein, contained in extracellular vesicles can be used as a biomarker for Alzheimer's disease. When the measured value of tau protein or phosphorylated tau protein in a sample collected from a subject is higher than the reference value, it can be determined that the subject has Alzheimer's disease.

[0045] Biomarkers reported for each disease include α-synuclein for Parkinson's disease and dementia with Lewy bodies; TAR DNA-binding protein (TDP-43) for amyotrophic lateral sclerosis and frontotemporal dementia; abnormal prion protein for Creutzfeldt-Jakob disease; and Neurofilament Light Chain for neurological dysfunction after cerebrospinal trauma, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, multiple system atrophy, triplet repeat disease, Alzheimer's disease, disease with Lewy bodies, frontotemporal dementia, vascular dementia, and corticobasal degeneration. Other examples include insulin-like growth factor-1 (IGF-1) and brain-derived neurotrophic factor (BDNF) for depression; microRNAs hsa-miR-34a and hsa-miR-432 for schizophrenia; and IGF-1 and BDNF for bipolar disorder.

[0046] The biomarker for neuropsychiatric disorders contained in extracellular vesicles can be detected as a polypeptide or a polynucleotide. The polynucleotide may be RNA or DNA, and RNA may include mRNA, microRNA, ncRNA, etc. The polypeptide and / or polynucleotide of the biomarker for neuropsychiatric disorders may be full-length or may include a fragment.

[0047] Methods for detecting biomarkers for psychiatric and neurological disorders as polypeptides include known methods such as Western blotting and enzyme-linked immunosorbent assay (ELISA). Methods for detecting biomarkers for psychiatric and neurological disorders as RNA include known methods such as RT-PCR (including quantitative RT-PCR), microarrays, and RNA-Seq. Methods for detecting biomarkers for psychiatric and neurological disorders as DNA include known methods such as PCR (including quantitative PCR), microarrays, and sequencing.

[0048] When biomarkers for neuropsychiatric disorders are detected as polypeptides by Western blotting, ELISA, or the like, extracellular vesicles are dissolved in a predetermined lysis buffer as a pretreatment. The sample dissolved in the lysis buffer is used as a test sample.

[0049] The primary antibody for detecting a biomarker for a neuropsychiatric disorder by Western blotting, ELISA, or the like is not limited as long as it can detect the biomarker for a neuropsychiatric disorder.

[0050] When biomarkers for neuropsychiatric disorders are detected as RNA using RT-PCR, microarrays, RNA-Seq, or the like, RNA is extracted from extracellular vesicles as a pretreatment. If necessary, the extracted RNA may be used as a template for reverse transcription to synthesize complementary DNA (cDNA). RNA or cDNA can be used to detect the biomarkers.

[0051] Commercially available primers (which may include a probe in the case of quantitative RT-PCR) can be used for RT-PCR, and commercially available microarrays can also be used.

[0052] RNA-Seq can obtain the number of reads of biomarker mRNA for neuropsychiatric disorders using a next-generation sequencer (for example, manufactured by Illumina).

[0053] When biomarkers for neuropsychiatric disorders are detected as DNA by PCR, microarray, sequencing, or the like, DNA is extracted from extracellular vesicles as a pretreatment. If necessary, an amplification reaction may be performed using the extracted DNA as a template. The DNA extracted from extracellular vesicles or the amplified DNA can be used to detect the biomarkers.

[0054] Commercially available primers (which may include a probe in the case of quantitative PCR) can be used for PCR, and commercially available microarrays can also be used.

[0055] Sequencing can be performed using a next-generation sequencer (for example, manufactured by Illumina) or the like to obtain the number of DNA reads associated with biomarkers for neuropsychiatric disorders.

[0056] When a biomarker for a neuropsychiatric disorder is detected by Western blotting, ELISA, RT-PCR, PCR, RNA-Seq, sequencing, microarray, or the like, if the biomarker for a neuropsychiatric disorder is detected in extracellular vesicles, it may be determined that "a biomarker for a neuropsychiatric disorder has been detected" or "expression of a biomarker for a neuropsychiatric disorder is positive." Alternatively, by comparing the amount of a polypeptide or polynucleotide of a biomarker for a neuropsychiatric disorder derived from extracellular vesicles of a subject with the amount of a polypeptide or polynucleotide of a biomarker for a neuropsychiatric disorder derived from extracellular vesicles of a healthy individual, it may be determined that "a biomarker for a neuropsychiatric disorder has been detected" or "expression of a biomarker for a neuropsychiatric disorder is positive." Furthermore, when the amount of a biomarker polypeptide or a biomarker polynucleotide for a neuropsychiatric disorder in extracellular vesicles derived from a subject is comparable to the amount of a biomarker polypeptide or a biomarker polynucleotide for a neuropsychiatric disorder in extracellular vesicles derived from a healthy individual, it may be determined that "a biomarker for a neuropsychiatric disorder is not detected" or that "expression of a biomarker for a neuropsychiatric disorder is negative." Here, "exhibiting a high value" can be exemplified by a value that is 1.2 times or more, preferably 1.5 times or more, more preferably 2 times or more, and even more preferably 5 times or more higher. "Similar levels" can be exemplified by a value between 0.8 times and less than 1.2 times. Furthermore, before comparing the amounts of a biomarker polypeptide or a biomarker polynucleotide for a neuropsychiatric disorder, the amount of extracellular vesicles purified from each sample may be normalized by the amount of a polypeptide marker for extracellular vesicles, such as CD9, CD63, or CD81. In addition, the number of extracellular vesicles may be normalized using the number of particles measured by Nanoparticle Tracking Analysis or the like.The amount of polypeptide may be expressed in terms of mass or concentration, or may be expressed in terms of the luminescence intensity of a substrate, etc. The amount of polynucleotide may be expressed in terms of the copy number or read number of a polynucleotide, or may be expressed in terms of fluorescence intensity, etc.

[0057] In another embodiment, a reference value for the amount of a biomarker polypeptide or RNA for a neuropsychiatric disorder may be determined in advance, and if the amount of a biomarker polypeptide or RNA for a neuropsychiatric disorder in extracellular vesicles derived from a subject is outside the reference range, it may be determined that "a biomarker for a neuropsychiatric disorder has been detected" or "expression of a biomarker for a neuropsychiatric disorder is positive." Alternatively, if the amount of a biomarker polypeptide or RNA for a neuropsychiatric disorder derived from extracellular vesicles derived from a subject is within the reference range, it may be determined that "a biomarker for a neuropsychiatric disorder has not been detected" or "expression of a biomarker for a neuropsychiatric disorder is negative." The reference value is not limited as long as it is a value that can determine whether the amount of a polypeptide of a biomarker for a neuropsychiatric disorder or the amount of a polynucleotide of a biomarker for a neuropsychiatric disorder has been detected or whether expression is positive, and can be determined by known methods. A value that can determine whether the amount of a polypeptide of a biomarker for a neuropsychiatric disorder or the amount of a polynucleotide of a biomarker for a neuropsychiatric disorder has been detected or whether expression is positive can also be determined by a receiver operating characteristic curve (ROC) curve, discriminant analysis method, mode method, Kittler method, 3σ method, p-tile method, etc. Examples of reference values ​​include sensitivity, specificity, negative predictive value, positive predictive value, and first quartile.

[0058] One embodiment of the method for detecting a biomarker for a neuropsychiatric disorder is a method for measuring total tau in extracellular vesicles, which comprises measuring total tau in extracellular vesicles obtained in the method for isolating extracellular vesicles from plasma using ultrasensitive digital ELISA.

[0059] 4. Method for recovering components derived from brain nerve cells In this embodiment, components derived from brain nerve cells are recovered using the extracellular vesicles recovered in 2 above.

[0060] The method for recovering components derived from brain nerve cells includes the step of recovering at least one biomolecule selected from the group consisting of sugars, lipids, polypeptides, and polynucleotides from the extracellular vesicles recovered in 1 above.

[0061] The sugars may include monosaccharides, disaccharides, oligosaccharides, and polysaccharides. The sugars may also be bound to lipids, proteins, etc. The sugars can be recovered from the extracellular vesicles by known methods using hydrazide-oxyamine-bearing polymers, lectins, etc.

[0062] Lipids may include fatty acids, eicosanoids, triacylglycerols, wax esters, phospholipids, sphingolipids, isoprenoids, lipoproteins, etc. Lipids can be extracted from extracellular vesicles using the Folch method, a Lipid Extraction Kit (Cell Biolabs, Inc.), or the like.

[0063] The polypeptides and polynucleotides may include the biomarkers described in 2 above, as well as components other than the biomarkers. The explanation of the biomarkers is incorporated herein by reference.

[0064] The polypeptides and polynucleotides can be recovered by known methods, or a commercially available extraction kit may be used.

[0065] 5. Test Reagent This section describes a test reagent for collecting extracellular vesicles. The test reagent contains the anti-APLP1 monoclonal antibody of the present invention. The description of the anti-APLP1 monoclonal antibody is incorporated herein by reference in Section 1 above.

[0066] The test reagent may contain one or more types of anti-APLP1 monoclonal antibodies.

[0067] The anti-APLP1 monoclonal antibody contained in the test reagent may be in a dry state or may be dissolved in a buffer such as phosphate-buffered saline. Furthermore, the test reagent may contain at least one of a stabilizer such as β-mercaptoethanol or DTT, a protectant such as albumin, a surfactant such as polyoxyethylene (20) sorbitan monolaurate or polyoxyethylene (10) octylphenyl ether, or a preservative such as sodium azide.

[0068] The anti-APLP1 monoclonal antibody may be labeled with an enzyme or a fluorescent dye. The antibody that binds to adipophilin may be immobilized on a microplate, magnetic beads, or the like.

[0069] 6. Test Kit In this section, a kit for recovering extracellular vesicles containing the test reagent described in 5 above will be described.

[0070] The test kit may be provided as a test kit including a test reagent and a package insert describing how to use the reagent or including a URL of a web page describing how to use the reagent. Furthermore, when the anti-APLP1 antibody is not bound to a carrier or solid phase, the test kit may include secondary antibody-bound beads, protein A beads, protein G beads, a secondary antibody-immobilized microplate, a protein A-immobilized microplate, a protein G-immobilized microplate, a secondary antibody-immobilized tube, or the like, for binding the anti-APLP1 antibody to a carrier or solid phase.

[0071] Furthermore, the test kit may include a size exclusion chromatography column, an affinity purification column, a polyether such as polyethylene glycol, etc. for crude purification of extracellular vesicles.

[0072] Furthermore, it may contain antibodies, probes, primers, etc. for detecting biomarkers for neuropsychiatric disorders present in extracellular vesicles.

[0073] The present invention will be described in more detail below based on examples. However, the examples are merely illustrative of the present invention and are not intended to limit the present invention.

[0074] Example 1-1 (Preparation of human APLP1-specific monoclonal antibody) (A) To prepare a human APLP1-specific monoclonal antibody, iliac lymph nodes were collected from guinea pigs immunized with the human APLP1 peptide (GTAVGDPSTRSWPPGSRVEG) (SEQ ID NO: 1), and a cell suspension was prepared from the iliac lymph nodes. 7 The cells were fixed in 2% paraformaldehyde in PBS at 4°C for 10 minutes (fixation).

[0075] The cells were collected by centrifugation, and 250 μl of staining solution (PBST containing anti-guinea pig IgG-Dylight 650, APLP1 peptide-streptavidin Dylight 488, streptavidin Dylight 550, and 200 units of RNase OUT) was added to the cells. The cells were then left on ice for 15 minutes for staining (cell membrane lysis and target antigen reaction).

[0076] To this solution, 3 ml of a PBS solution containing 0.2 μg / ml of DAPI was added to stain the cell nuclei.

[0077] These cells were analyzed using a flow cytometer to isolate APLP1 peptide-specific plasma cells. Single-cell populations were identified by setting the R1 gate (FSC vs. SSC) and the R2 gate (DAPI). Autofluorescent and nonspecifically stained cells were then removed from the single-cell population using the FL2 channel (R3 gate). Among these cells, cells strongly positive for anti-mouse IgG, strongly positive for APLP1 peptide, and negative for streptavidin Dylight550 were identified as APLP1 peptide-specific plasma cells (R4 gate). The results are shown in Figure 3.

[0078] (C) Cells in the R4 gate were subjected to single-cell sorting (cell isolation). Subsequently, cDNA was synthesized from the cells separated by the cell sorter according to the method of Kurosawa et al. (Non-Patent Documents 2 and 3), and the rat γ-chain and κ-chain variable region genes were amplified using this as a template by 5'-RACE PCR. The amplified variable regions were inserted into a linearized expression vector to generate guinea pig γ-chain and κ-chain immunoglobulin expression units. The results of agarose gel electrophoresis of the amplified DNA are shown.

[0079] From the obtained variable region genes, full-length heavy and light chain immunoglobulin genes were created according to the method of Kurosawa et al. (Non-Patent Documents 2 and 3), and these were then introduced into 293FT cells to produce recombinant antibodies. The reactivity of the obtained antibodies to APLP1 peptides was analyzed by ELISA. Of these, antibody #11 showed the highest reactivity to APLP1 peptides. The results are shown in Figure 4.

[0080] Using the obtained APLP1 peptide-positive antibody clone, we performed immunostaining on SHSY-5Y cells, a human neuroblastoma that expresses endogenous APLP1, and on APLP1 gene knockout SHSY-5Y cells. #11 showed dot-like localization in the cytoplasm of SHSY-5Y cells, but no signal was observed in the knockout cells. The results are shown in Figure 5.

[0081] Extracts from HEK293 cells overexpressing the human APLP1 gene were separated by SDS electrophoresis and subjected to Western blotting using antibody #11 as the primary antibody. A single band was observed at 75 kDa, corresponding to the molecular weight of APLP1, in the overexpressing HEK293 cells, whereas no signal was observed in the negative control wild-type HEK293 cells. The results are shown in Figure 6.

[0082] The amino acid sequence of human APLP1 (SEQ ID NO: 1) is shown in FIG. 2, the #11 light chain amino acid sequence (SEQ ID NO: 2) is shown in Table 3, and the #11 heavy chain amino acid sequence (SEQ ID NO: 3) is shown in Table 4.

[0083]

[0084]

[0085] Example 1-2 (Identification of the Minimal Epitope of a Human APLP1-Specific Monoclonal Antibody) Fusion proteins in which APLP1-derived peptide sequences (RSWPPGSRVE (SEQ ID NO: 20), RSWPPGSRV (SEQ ID NO: 21), WPPGSRVE (SEQ ID NO: 22), PPGSRVE (SEQ ID NO: 23), PGSRVE (SEQ ID NO: 24)) were added to the C-terminus of GFP were expressed in HEK293 cells by gene transfer. After 24 hours of culture, the cells were fixed with 4% formalin / PBS, membranes were solubilized with 0.1% TritonX-100 / PBS, and then incubated with #11 (0.1 μg / mL PBS) for 1 hour. Signals were detected by cell staining with an anti-guinea pig antibody (Dylight 650). The results are shown in Figure 7.

[0086] Results: When the peptide RSWPPGSRVE was added to GFP, GFP-positive cells were positive for #11, but when the peptide RSWPPGSRV was added to GFP, GFP-positive cells were not positive for #11. This indicates that E is required for the C-terminal epitope recognized by #11.

[0087] Next, when the peptide PPGSRVE was added to GFP, GFP-positive cells were positive for #11, but when the peptide PGSRVE was added to GFP, GFP-positive cells were not positive for #11. These results revealed that the minimal epitope recognized by #11 is PPGSRVE.

[0088] Example 1-3 (1) APLP1 cDNA was introduced into HEK293 cells, and after 48 hours of culture, the cells were treated with 0.1% TritonX-100 / PBS to obtain a cell extract. Proteins in the cell extract (equivalent to 10 μg) were separated using SDS-polyacrylamide and transferred to a nitrocellulose membrane, followed by detection of APLP1 using #11. The results are shown in Figure 8. A band corresponding to the molecular weight of APLP1, 75 kDa, was detected.

[0089] (2) SHSY-5Y cells were fixed in 4% formalin / PBS, membranes were solubilized in 0.1% Triton X-100 / PBS, and then incubated with #11 (0.1 μg / mL PBS) for 12 hours. Signals were detected by staining the cells with an anti-guinea pig antibody (Dylight 650). The results are shown in Figure 9.

[0090] Example 2: Recovery of brain neuron-derived extracellular vesicles from plasma using human APLP1-specific monoclonal antibody #11 (1) Sample: Blood was collected from healthy adults using EDTA-2K tubes, and 20 mL of plasma was separated. The plasma was stored at -80°C until testing. Before use, the plasma was thawed and centrifuged at 2,500 × g and 4°C for 10 minutes, and the supernatant was collected.

[0091] (2) Crude Purification of Plasma Extracellular Vesicles Using qEV10 (Izon Science), 20 mL of size-exclusion chromatography (SEC) fraction was collected from 10 mL of plasma according to the kit protocol. This procedure was repeated twice, and 40 mL of SEC fraction was collected. The SEC fraction was concentrated to 3,000 μL using an Amicon Ultra-15 100 kDa MWCO column.

[0092] (3) Preparation of beads for immunoprecipitation Human APLP1-specific monoclonal antibody #11 prepared in Example 1 was biotinylated using EZ-Link NHS-PEG4-Biotin No-Weigh Format (Thermo Fisher Scientific) according to the protocol provided with the kit, and excess biotin was removed and purified using Zeba Spin Desalting Columns 40K MWCO 0.5 mL (Thermo Fisher Scientific) according to the protocol provided with the kit.

[0093] 20 μL of Dynabeads® MyOne Streptavidin C1 (Thermo Fisher Scientific) and 10 μg of biotinylated human APLP1-specific monoclonal antibody #11 were mixed in Dulbecco's PBS containing 0.01% Tween-20 to prepare magnetic beads to which human APLP1-specific monoclonal antibody #11 was bound.

[0094] Furthermore, ECL TM Antibody-bound magnetic beads were added to 800 μL of blocking buffer containing 2% (w / v) Prime Blocking Reagent, and the mixture was incubated overnight at 4° C. to block the surface.

[0095] (4) Immunoprecipitation of brain neuron-derived extracellular vesicles 1,444 μL of concentrated SEC fraction was added to the immunoprecipitation beads prepared in (3) above and incubated at 4°C for 6 hours with end-over-end mixing. The tube was spun down, attached to a magnetic stand, and left for 1 minute, after which the supernatant was removed. Next, to wash the magnetic beads, 800 μL of D-PBS(-) was added to the tube and mixed by end-over-end mixing. The tube was spun down again, attached to a magnetic stand, and left for 1 minute, after which the supernatant was removed. The tube was spun down again, attached to a magnetic stand, and left for 1 minute, after which the supernatant was completely removed.

[0096] To the tube containing the remaining magnetic beads, 17.4 μL of 0.1 M glycine-HCl (pH 2.8) was added, vortexed, and then incubated at 4°C for 10 minutes. The tube was spun down, placed on a magnetic stand, and left for 1 minute. The supernatant was then collected and the pH was adjusted by adding 2.6 μL of 1 M Tris-HCl (pH 8.0) before analysis.

[0097] (5) Western Blot: The supernatant collected in the previous step was mixed with a denaturing buffer and heated to prepare the sample for application. The sample was loaded onto a 5-15% Tris-glycine SDS gel and electrophoresed at 200 V for 55 minutes. After electrophoresis, the SDS gel was electrophoresed under semi-dry conditions in Towbin Buffer (containing 5% methanol) at 15 V for 30 minutes, and then transferred from the gel to a PVDF membrane.

[0098] Blocking was performed using Blocking One (Nacalai Tesque, Inc.) at room temperature for 5 minutes. Primary antibodies were diluted in 5% Blocking One dissolved in TBS-T and incubated overnight at 4°C. The antibodies used were anti-APLP1 (R&D Systems, AF3129), anti-CD81 (Cosmo Bio, SHI-EXO-M03), and anti-CD9 (Cosmo Bio, SHI-EXO-M01). The anti-APLP1 and anti-CD81 antibodies were diluted 2,000-fold, and the anti-CD9 antibody was diluted 1,000-fold. After incubation with the primary antibodies, the cells were washed six times with TBS-T for 5 minutes each.

[0099] The secondary antibody was diluted with 5% Blocking One in TBS-T and incubated at room temperature for 1 hour. The antibodies used were HRP-labeled anti-mouse antibody (Promega, W4021) and HRP-labeled anti-rabbit antibody (Promega, W4011), all diluted 10,000 times. The cells were washed six times with TBS-T, each for 5 minutes.

[0100] 1,400 μL of ImmunoStar® LD A+B solution was added to the membrane and incubated at room temperature for 5 minutes. HRP was developed using a MyECL Imager (Thermo Scientific), and the signal was imaged.

[0101] (6) Results The results of Western Blot are shown in Figure 10-1.

[0102] Immunoprecipitation using plasma detected the target APLP1 as well as EV proteins CD81 and CD9, demonstrating that the use of specific monoclonal antibody #11 enabled the isolation of APLP1-positive EVs, which are brain neuron-derived extracellular vesicles.

[0103] Furthermore, in immunoprecipitation using plasma, the detection of APLP1 and the EV proteins CD9 and CD63 was compared using the specific monoclonal antibody #11 of the present invention or a commercially available polyclonal antibody (Human APLP-1 Antibody (R&D Systems, #AF3129)). The results of Western blot are shown in Figure 10-2. As a result, APLP1, CD9, and CD63 could be detected using the specific monoclonal antibody #11. In contrast, when a commercially available polyclonal antibody was used, APLP1 could not be detected, and detection of CD9 and CD63 was also difficult.

[0104] Example 3 Recovery of extracellular vesicles from culture supernatant of neurons differentiated from iPS cells (1) Preparation of beads for immunoprecipitation Human APLP1-specific monoclonal antibody #11 prepared in Example 1 was biotinylated using EZ-Link NHS-PEG4-Biotin No-Weigh Format (Thermo Fisher Scientific) according to the protocol provided with the kit, and excess biotin was removed and purified using Zeba Spin Desalting Columns 40K MWCO 0.5 mL (Thermo Fisher Scientific) according to the protocol provided with the kit.

[0105] 20 μL of Dynabeads® MyOne Streptavidin C1 (Thermo Fisher Scientific) and 10 μg of biotinylated human APLP1-specific monoclonal antibody #11 were mixed in Dulbecco's PBS containing 0.01% Tween-20 to prepare magnetic beads to which human APLP1-specific monoclonal antibody #11 was bound.

[0106] Furthermore, ECL TMAntibody-bound magnetic beads were added to 800 μL of blocking buffer containing 2% (w / v) Prime Blocking Reagent, and the mixture was incubated overnight at 4° C. to block the surface.

[0107] (2) Preparation of extracellular vesicles (EVs) from culture supernatant. Culture supernatant from neurons differentiated from iPS cells was centrifuged at 2,500 g for 10 minutes, and 80 mL of the supernatant was concentrated to 20 mL using an Amicon Ultra-15 100 kDa MWCO. Using the qEV10 (Izon Science) according to the kit protocol, 20 mL of size exclusion chromatography (SEC) fraction was collected from 10 mL of concentrated culture supernatant. This procedure was repeated twice, and 40 mL of SEC fraction was collected. The SEC fraction was concentrated to 1,300 μL using an Amicon Ultra-15 100 kDa MWCO.

[0108] (3) Immunoprecipitation and Western Blot 300 μL of concentrated SEC fraction was added to the immunoprecipitation beads and incubated at 4°C for 8 hours with end-over-end mixing. The tube was spun down, attached to a magnetic stand, and left for 1 minute, after which the supernatant was removed. Next, to wash the magnetic beads, 800 μL of D-PBS(-) was added to the tube and mixed by end-over-end mixing. The tube was spun down again, attached to a magnetic stand, and left for 1 minute, after which the supernatant was removed. The tube was spun down again, attached to a magnetic stand, and left for 1 minute, after which the supernatant was completely removed.

[0109] 64 μL of 1x RIPA buffer (without SDS) (Nacalai Tesque, Inc., 08714-04), prepared according to the kit instructions, was added to the tube containing the beads, vortexed, and incubated at 4°C for 10 minutes. After centrifugation, the tube was attached to a magnetic stand and left to stand for 1 minute. The supernatant was collected, mixed with denaturing buffer, and heated to prepare the sample for application. The sample was loaded onto a 5-15% Tris-glycine SDS gel and electrophoresed at 200 V for 55 minutes. After electrophoresis, the SDS gel was electrophoresed under semi-dry conditions in Towbin Buffer (containing 5% methanol) at 15 V for 30 minutes, and then transferred from the gel to a PVDF membrane.

[0110] Blocking was performed using Blocking One (Nacalai Tesque, Inc.) at room temperature for 5 minutes. APLP1 C-terminal antibody (Calbiochem 171615) diluted 10,000 times in 5% Blocking One dissolved in TBS-T, CD63 antibody (Santa Cruz sc-5275) diluted 2,000 times, and CD81 antibody (Santa Cruz sc-23962) diluted 2,000 times were added and incubated overnight at 4°C with shaking. After incubation, the membrane was washed six times for 5 minutes with 0.1% TBS-T.

[0111] The secondary antibody was diluted with 5% Blocking One in TBS-T and incubated at room temperature for 1 hour. The antibodies used were HRP-labeled anti-mouse antibody (Promega, W4021) and HRP-labeled anti-rabbit antibody (Promega, W4011), all diluted 10,000 times. The cells were washed six times with TBS-T, each for 5 minutes.

[0112] 800 μL each of ImmunoStar® LD (Wako) solution A and solution B were mixed, and the membrane was immersed in the solution and left to stand for 5 minutes. Signals were detected using a MY ECL Imager (Thermo Fisher Scientific) (10-300 seconds).

[0113] (4) Results The results of Western Blot are shown in FIG.

[0114] Lane 1 is 1 μg of iPS neuron lysate, lane 2 is EV before immunoprecipitation, lane 3 is input, lane 4 is the supernatant from immunoprecipitating EV, and lane 5 is antibody-coupled beads from immunoprecipitating EV. 1 / 40 of the total input and supernatant was electrophoresed.

[0115] APLP1, EV marker proteins (CD63, Flotillin-1), and neural-derived proteins (L1CAM, SNAP25) were detected with antibody beads, demonstrating that extracellular vesicles can be recovered using human APLP1-specific monoclonal antibody #11.

[0116] Example 4 Comparison of Total Tau Amount in CSF and NDE, and Comparison of Total Tau Amount in NDE with Phosphorylated Tau (pTau181) and Aβ42 / Aβ40 in CSF (1) Samples Blood was collected from patients using EDTA-2K tubes, and 10 mL of plasma was separated. The plasma was stored at -80°C until testing. Before use, the plasma was thawed and centrifuged at 10,000 × g at room temperature for 5 minutes, and the supernatant was collected. 100 μL of D-PBS(-) was added to 400 μL of plasma.

[0117] (2) Crude purification of plasma extracellular vesicles Using qEV original (Izon Science), 1,500 μL of size exclusion chromatography (SEC) fraction was collected from 500 μL of D-PBS(-)-added plasma according to the protocol attached to the kit.

[0118] (3) Preparation of beads for immunoprecipitation Human APLP1-specific monoclonal antibody #11 prepared in Example 1 was biotinylated using EZ-Link NHS-PEG4-Biotin No-Weigh Format (Thermo Fisher Scientific) according to the protocol provided with the kit, and excess biotin was removed and purified using Zeba Spin Desalting Columns 40K MWCO 0.5 mL (Thermo Fisher Scientific) according to the protocol provided with the kit.

[0119] Ten microliters of Dynabeads® MyOne Streptavidin C1 (Thermo Fisher Scientific) and 4 μg of biotinylated human APLP1-specific monoclonal antibody #11 were mixed in D-PBS(-) containing 0.01% Tween-20 to prepare magnetic beads to which the specific monoclonal antibody #11 was bound.

[0120] Furthermore, ECL TM Antibody-bound magnetic beads were added to 800 μL of blocking buffer containing 2% (w / v) Prime Blocking Reagent, and the mixture was incubated overnight at 4° C. to block the surface.

[0121] (4) Immunoprecipitation of brain neuron-derived extracellular vesicles 1,444 μL of concentrated SEC fraction was added to the immunoprecipitation beads prepared in (3) above and incubated at 4°C for 6 hours with end-over-end mixing. The tube was spun down, attached to a magnetic stand, and left for 1 minute, after which the supernatant was removed. Next, to wash the magnetic beads, 800 μL of D-PBS(-) was added to the tube and mixed by end-over-end mixing. The tube was spun down again, attached to a magnetic stand, and left for 1 minute, after which the supernatant was removed. The tube was spun down again, attached to a magnetic stand, and left for 1 minute, after which the supernatant was completely removed.

[0122] To the tube containing the remaining magnetic beads, 105 μL of 0.1 M glycine-HCl (pH 2.8) was added, vortexed, and then incubated at 4°C for 10 minutes. The tube was spun down, placed on a magnetic stand, and left for 1 minute. The supernatant was then collected and the pH was adjusted by adding 15.8 μL of 1 M Tris-HCl (pH 8.0) before analysis.

[0123] (5) Simoa Tau 2.0 assay: The supernatant collected in the previous step was dispensed into a dedicated 96-well plate, and the tau concentration was measured using the Simoa HD-1 Analyzer and Simoa Tau 2.0 Advantage Kit according to the kit instructions. This resulted in the determination of the total amount of tau contained in extracellular vesicles isolated from plasma using human APLP1-specific monoclonal antibody #11.

[0124] Cerebrospinal fluid (CSF) was collected by lumbar puncture on the same day as plasma collection in (1). The CSF was centrifuged at 430 × g for 5 minutes at room temperature, aliquoted, and stored at −80°C. Total tau, phosphorylated tau (pTau181), Aβ42, and Aβ40 levels were measured by sandwich ELISA.

[0125] (6) Results Figure 12 shows a scatter plot showing the correlation between the measured total tau amount in plasma brain neuron-derived extracellular vesicles and the total tau amount in cerebrospinal fluid. Figure 13 shows a scatter plot showing the correlation between the measured total tau amount in plasma brain neuron-derived extracellular vesicles and phosphorylated tau (pTau181) (left panel) and the Aβ42 / Aβ40 ratio (right panel).

[0126] The total tau levels in extracellular vesicles isolated by immunoprecipitation using human APLP1-specific monoclonal antibody #11 and plasma correlated well with the total tau, phosphorylated (pTau181), and Aβ42 / Aβ40 ratios in cerebrospinal fluid (CSF). These results demonstrate that APLP1-positive EVs, which are brain neuron-derived extracellular vesicles, can be isolated and reflect the biomarker levels in CSF. Furthermore, the total tau levels in extracellular vesicles isolated from plasma using human APLP1-specific monoclonal antibody #11 could be a biomarker for neuropsychiatric disorders. The total tau levels detected by this method could be used to detect neuropsychiatric disorders using plasma, which is easily accessible, instead of CSF, which is difficult to obtain.

[0127] The present invention is useful in fields related to biomarkers for neuropsychiatric disorders.

[0128] SEQ ID NO: 1: Human APLP1 amino acid sequence (NCBI accession no. NP_031493.2) SEQ ID NO: 2: #11 light chain amino acid sequence SEQ ID NO: 3: #11 heavy chain amino acid sequence SEQ ID NO: 4: #11 light chain FR1 SEQ ID NO: 5: #11 light chain CDR1 SEQ ID NO: 6: #11 light chain FR2 SEQ ID NO: 7: #11 light chain CDR2 SEQ ID NO: 8: #11 light chain FR3 SEQ ID NO: 9: #11 light chain CDR3 SEQ ID NO: 10: #11 light chain FR4 SEQ ID NO: 11: #11 heavy chain FR1 SEQ ID NO: 12: #11 heavy chain CDR1 SEQ ID NO: 13: #11 heavy chain FR2 SEQ ID NO: 14: #11 heavy chain CDR2 SEQ ID NO: 15: #11 heavy chain FR3 SEQ ID NO: 16: #11 heavy chain CDR3 SEQ ID NO: 17: #11 heavy chain FR4 SEQ ID NO: 18: #11 light chain signal sequence SEQ ID NO: 19: #11 heavy chain signal sequence SEQ ID NO: 20: Peptide sequence for identifying minimal epitope SEQ ID NO: 21: Peptide sequence for identifying minimal epitope SEQ ID NO: 22: Peptide sequence for identifying minimal epitope SEQ ID NO: 23: Peptide sequence for identifying minimal epitope SEQ ID NO: 24: Peptide sequence for identifying minimal epitope

Claims

1. An anti-APLP1 monoclonal antibody having as its epitope the amino acid sequence from positions 232 to 238 of the amino acid sequence set forth in SEQ ID NO:1 of the Sequence Listing.

2. An anti-APLP1 monoclonal antibody in which the light chain CDR1, CDR2 and CDR3 have the amino acid sequences set forth in SEQ ID NOs: 5, 7 and 9, respectively, and the heavy chain CDR1, CDR2 and CDR3 have the amino acid sequences set forth in SEQ ID NOs: 12, 14 and 16, respectively.

3. The anti-APLP1 monoclonal antibody described in claim 2, in which FR1, FR2, FR3 and FR4 of the light chain have the amino acid sequences of SEQ ID NOs: 4, 6, 8 and 10, respectively, and FR1, FR2, FR3 and FR4 of the heavy chain have the amino acid sequences of SEQ ID NOs: 11, 13, 15 and 17, respectively.

4. A method for recovering extracellular vesicles derived from brain neurons, comprising: a step of mixing a sample containing an anti-APLP1 antibody and extracellular vesicles to form a complex of the anti-APLP1 antibody and the extracellular vesicles; and a step of recovering the complex of the anti-APLP1 antibody and the extracellular vesicles, wherein the anti-APLP1 antibody is an anti-APLP1 monoclonal antibody described in claim 1 or 2.

5. The method of claim 4, wherein the sample containing extracellular vesicles is plasma.

6. A method for detecting a biomarker for a psychiatric and neurological disorder, comprising the steps of recovering extracellular vesicles by the method described in claim 4, and obtaining measurement values ​​of polypeptides and / or polynucleotides that are biomarkers for the psychiatric and neurological disorder from the recovered extracellular vesicles.

7. The method of claim 6, further comprising the step of comparing the obtained measurements with corresponding reference values ​​to determine whether the measurements are within or outside of a reference range.

8. The detection method according to claim 6, wherein the biomarker is tau protein or phosphorylated tau protein.

9. A method for recovering components derived from brain nerve cells, comprising the steps of recovering extracellular vesicles by the method described in claim 4, and recovering at least one biological molecule selected from the group consisting of sugars, lipids, polypeptides, and polynucleotides from the recovered extracellular vesicles.

10. A test reagent used for recovering extracellular vesicles, comprising the anti-APLP1 monoclonal antibody according to claim 1 or 2.

11. The test reagent according to claim 10, which is used to carry out the method for recovering extracellular vesicles according to claim 4.

12. The test reagent according to claim 10, which is used to carry out the method for detecting a biomarker for a neuropsychiatric disorder according to claim 6.

13. The test reagent according to claim 10, which is used to carry out the method for recovering components derived from brain nerve cells according to claim 9.

14. A test kit comprising the test reagent according to claim 10.

Citation Information

Patent Citations

  • Amyloid precursor like protein and its use

    JP1994128294A

  • Brain-derived vesicle-specific marker and brain disease diagnostic method using same

    US20220099686A1

  • Method for collecting extracellular vesicles derived from nervous system cells

    WO2021132352A1